BCOR and ZC3H12A suppress a core stemness program in exhausted CD8+ T cells.

J Exp Med

State Key Laboratory of Molecular Oncology, Institute for Immunology, Beijing Key Laboratory of Immunological Research of Allergy, School of Basic Medical Sciences, Tsinghua University, Beijing, China.

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

In chronic viral infections, sustained CD8+ T cell response relies on TCF1+ precursor-exhausted T cells (TPEX) exhibiting stem-like properties. TPEX self-renew and respond to PD-1 blockade, underscoring their paramount importance. However, strategies for effectively augmenting TPEX remain limited. Here, we demonstrate that ZC3H12A deficiency initiates a stemness program in TPEX but also increases cell death, whereas BCOR deficiency predominantly promotes TPEX proliferation. Consequently, co-targeting of both BCOR and ZC3H12A imparts exceptional stemness and functionality to TPEX, thereby enhancing viral control. Mechanistically, BCOR and ZC3H12A collaboratively suppress a core stemness program in TPEX characterized by heightened expression of ∼216 factors. While TCF1 plays a role, this core stemness program relies on novel factors, including PDZK1IP1, IFIT3, PIM2, LTB, and POU2F2. Crucially, overexpressing POU2F2 robustly boosts TPEX and enhances antiviral immunity. Thus, a core stemness program exists in exhausted T cells, jointly repressed by BCOR and ZC3H12A, robustly controlling TPEX differentiation and providing new targets for addressing T cell exhaustion.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12054362PMC
http://dx.doi.org/10.1084/jem.20241133DOI Listing

Publication Analysis

Top Keywords

stemness program
20
bcor zc3h12a
16
core stemness
16
tpex
9
suppress core
8
program tpex
8
stemness
6
bcor
5
program
5
zc3h12a suppress
4

Similar Publications

RELA Ablation Contributes to Progression of Hepatocellular Carcinoma with TP53 Mutation and is a Potential Therapeutic Target.

Adv Sci (Weinh)

September 2025

China-New Zealand Joint Laboratory on Biomedicine and Health, State Key Laboratory of Immune Response and Immunotherapy, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, GIBH-HKU Guangdong-Hong Kong Stem Cell and Regenerative Medicine Research Centre, GIBH-CUHK Joint Resea

TP53 mutations are highly associated with hepatocellular carcinoma (HCC), a common and deadly cancer. However, few primary drivers in the progression of HCC with mutant TP53 have been identified. To uncover tumor suppressors in human HCC, a genome-wide CRISPR/Cas9-based screening of primary human hepatocytes with MYC and TP53 overexpression (MT-PHHs) is performed in xenografts.

View Article and Find Full Text PDF

Anti-epidermal growth factor receptor (EGFR) therapies are the most recommended first-line treatment for wild-type unresectable metastatic colorectal cancer (CRC) according to the European Society for Medical Oncology guidelines. However, primary resistance renders this treatment ineffective for almost 40% of patients. Our previous work identified Aurora kinase A (AURKA) as a key resistance driver through non-canonical, Hippo-independent Yes-associated protein 1 (YAP1) activation.

View Article and Find Full Text PDF

Cancer stem cells in focus: Deciphering the dynamic functional landscape of stemness in cancer.

Biochim Biophys Acta Rev Cancer

September 2025

Institute of Cancer Therapeutics, Faculty of Life Sciences, University of Bradford, Bradford, United Kingdom. Electronic address:

Cancer stem cells (CSCs) are central to tumour initiation, progression, and relapse, yet their dynamic and adaptive nature hampers therapeutic targeting. Once viewed as a fixed subpopulation, CSCs are now recognised as a fluid functional state that tumour cells can enter or exit, driven by intrinsic programs, epigenetic reprogramming, and microenvironmental cues. This plasticity complicates identification due to inconsistent marker expression and enables resistance, dormancy, and metastasis.

View Article and Find Full Text PDF

Rosuvastatin-loaded injectable immunomodulatory hydrogel mitigates local immune response against transplanted stem cells and promotes heart repair in vivo.

Biomater Adv

August 2025

Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Department of Physiology and Pathophysiology, Rady Faculty of Health Sciences, Biomedical Engineering Program, University of Manitoba, Winnipeg, Manitoba R2H 2A6, Canada. Electronic address:

In clinical trials allogeneic mesenchymal stem cells (MSCs) from young and healthy donors have shown promise to repair the heart following a heart attack. However, immune rejection of transplanted MSCs has prevented the clinical translation of stem cells-based therapies for cardiac patients. Therefore, strategies to improve survival of implanted stem cells in the heart would be of immense therapeutic value.

View Article and Find Full Text PDF

Bibliometric-driven research on chemoresistance in breast cancer: knowledge mapping, hotspot evolution, and emerging insights (1994-2024).

Discov Oncol

September 2025

Department of Biomedical Sciences, Advanced Medical and Dental Institute (IPPT), Universiti Sains Malaysia, SAINS@Bertam, Kepala Batas, Penang, 13200, Malaysia.

Background: Chemoresistance remains a pivotal challenge in the clinical management of breast cancer. A systematic dissection of global research trends, evolutionary hotspots, and emerging frontiers in this field is imperative for advancing therapeutic strategies.

Methods: Relevant literature on breast cancer chemoresistance from 1994 to 2024 was retrieved from the Science Citation Index-Expanded (SCI-E) database of the Web of Science Core Collection (WoSCC).

View Article and Find Full Text PDF